• Mark Jit, Kiesha Prem, Elodie Benard, and Marc Brisson.
• Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom; School of Public Health, University of Hong Kong, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China. Electronic address: mark.jit@lshtm.ac.uk.
• Prev Med. 2021 Mar 1; 144: 106354.

AbstractThe Director-General of the World Health Organization has called for global action towards elimination of cervical cancer as a public health problem. Cervical cancer is caused by human papillomavirus (HPV), an infectious agent with no non-human reservoir. One way to achieve this is through very high levels of vaccine coverage that could enable global eradication of vaccine-type HPV. Using the case study of India, we show that HPV eradication can meet all the Dahlem and Strüngmann criteria for feasibility of eradication. It can be achieved with 90% gender-neutral HPV vaccine coverage together with 95% coverage in high-risk groups such as female sex workers. Such a strategy would likely be cost-effective compared to no vaccination. Although it would be more costly in the short-term than achieving cervical cancer elimination alone, it would save costs in the long-term by removing or at least sharply reducing the need for preventive measures.Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

19 keywords...

hide…